Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Shell PLC — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Shell PLC trades at $104.77 (market cap $290.47B). The key difference: Shell PLC is far larger — about 32.7× Kymera Therapeutics Inc. Common Stock's market cap, and Shell PLC pays a 3.03% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Shell PLC for 91 Days on average.
| KYMR | SHEL | |
|---|---|---|
Market Cap | $8.87B | $290.47B |
Volume | 779,107 | 4,901,394 |
Sector | Health | Energy |
52-Week High | $127.31 | $103.58 |
52-Week Low | $55.80 | $70.31 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $8.26B | $332.17B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Shell (SHEL) trades at $103.58, up 1.96% today, near its consensus price target of $103.24. The stock shows bullish momentum with strong earnings beats in Q1 and Q2 2026, though Q4 2025 missed estimates. Recent news highlights expansion in LNG Canada Phase 2, doubling export capacity. Valuation metrics appear reasonable with a P/E of 11.39 and EV/EBITDA of 4.89. Operating cash flow remains robust at $42.86 billion for 2025, supporting dividend payments and strategic investments.
Outlook is positive with analyst consensus favoring Buy ratings (61.54%) and a high price target of $122.40. Key opportunities include LNG growth and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock's current technical overbought condition may prompt near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
